Long-term Study of KAD-1229 in Type 2 Diabetes Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01333592
Recruitment Status : Completed
First Posted : April 12, 2011
Results First Posted : November 24, 2014
Last Update Posted : December 15, 2014
Information provided by:
Kissei Pharmaceutical Co., Ltd.

Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Type 2 Diabetes
Intervention: Drug: KAD-1229

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
KAD-1229 / DPP-4 Inhibitors No text entered.
KAD-1229 / Biguanides No text entered.

Participant Flow:   Overall Study
    KAD-1229 / DPP-4 Inhibitors   KAD-1229 / Biguanides
STARTED   67   69 
COMPLETED   58   52 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
One patient in the KAD-1229 / biguanides group was excluded because of early discontinuation and no evaluable HbA1c.

Reporting Groups
KAD-1229 / DPP-4 Inhibitors No text entered.
KAD-1229 / Biguanides No text entered.
Total Total of all reporting groups

Baseline Measures
   KAD-1229 / DPP-4 Inhibitors   KAD-1229 / Biguanides   Total 
Overall Participants Analyzed 
[Units: Participants]
 67   68   135 
[Units: Years]
Mean (Standard Deviation)
 60.3  (10.6)   56.9  (11.5)   58.6  (11.1) 
[Units: Participants]
Female   21   18   39 
Male   46   50   96 
[Units: %]
Mean (Standard Deviation)
 7.47  (0.54)   7.50  (0.66)   7.49  (0.60) 

  Outcome Measures

1.  Primary:   Incidences of Adverse Events   [ Time Frame: 52 weeks ]

2.  Secondary:   Change From Baseline in HbA1c at 52 Weeks   [ Time Frame: at week 0 and week 52 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Clinical Development Division
Organization: Kissei Pharmaceutical Co., Ltd
e-mail: Identifier: NCT01333592     History of Changes
Other Study ID Numbers: KAD4301
First Submitted: April 6, 2011
First Posted: April 12, 2011
Results First Submitted: November 17, 2014
Results First Posted: November 24, 2014
Last Update Posted: December 15, 2014